Lineage Cell The Stock Price, News & Analysis

Lineage Cell Therapeutics (NYSE American: LCTX) announced that CEO Brian M. Culley will present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021, at 1:30 p.m. ET. The presentation will be a virtual fireside chat hosted by B. Riley Equity Research. Interested investors can access the live and archived webcast on the Events and Presentations section of Lineage’s website.

Lineage Cell Therapeutics (NYSE American: LCTX) has appointed Dr. Dipti Amin to its Board of Directors as of April 20, 2021. Dr. Amin, a seasoned Non-Executive Director with over 26 years in the pharmaceutical sector, brings extensive experience in clinical research, drug development, and compliance. The company’s Chairman, Al Kingsley, emphasized her ability to significantly advance Lineage’s mission to lead in allogeneic cell transplants. Dr. Amin expressed her enthusiasm about contributing to the company’s growth and guiding its product candidates towards later-stage clinical trials.

Lineage Cell Therapeutics (LCTX) announced a global licensing and collaboration agreement with Immunomic Therapeutics (ITI) to develop a new product candidate aimed at treating glioblastoma multiforme (GBM). This partnership will utilize Lineage's VAC cancer immunotherapy platform and ITI's proprietary Tumor Associated Antigen. Lineage will receive an upfront payment of $2 million and could earn up to $67 million in development and commercial milestones, plus royalties of up to 10% on future sales. This collaboration is expected to diversify Lineage's oncology pipeline and enhance its therapeutic offerings.

Lineage Cell Therapeutics (NYSE: LCTX) announced updated interim results from a Phase 1/2a study of OpRegen®, a cell therapy aimed at treating dry age-related macular degeneration (AMD). The study enrolled 24 patients in four cohorts, assessing safety, tolerability, and preliminary efficacy. Notably, Cohort 4 utilized a new 'thaw-and-inject' formulation, enhancing logistical efficiency. Results will be presented at the 2021 ARVO Annual Meeting on May 6, 2021. Dry AMD affects 85-90% of AMD cases, and no FDA-approved treatments currently exist for this condition.

Lineage Cell Therapeutics (NYSE American: LCTX) announced the compassionate use treatment of a patient with adult-onset vitelliform macular dystrophy (AVMD) using its cell therapy product, OpRegen, at Hadassah-Hebrew University Medical Center. This treatment follows approval from the Israeli Ministry of Health and aims to address the underlying retinal cell damage related to the disease. OpRegen, currently in a Phase 1/2a trial for dry age-related macular degeneration, employs allogeneic retinal pigment epithelium cells. The patient remains under follow-up care post-treatment.

Lineage Cell Therapeutics (NYSE American: LCTX) announced positive interim results from its Phase 1/2a clinical study of OpRegen, a cell therapy for dry age-related macular degeneration (AMD) with geographic atrophy (GA). In Cohort 4, 75% of patients showed maintained or improved visual acuity, with enhancements of up to +19 letters on an EDTRS chart. Notably, OpRegen has exhibited durability, with some patients demonstrating stable outcomes after over 5 years. The study utilized minimal immunosuppression, with no unexpected adverse events reported, suggesting potential for effective long-term treatment.

Lineage Cell Therapeutics (NYSE American and TASE: LCTX) announced that CEO Brian M. Culley will present at the Benzinga Global Biotech Small Cap conference on March 24, 2021, at 11:50 AM ET. He will also participate in a panel discussion titled “Coming Together to Address Unmet Medical Needs” at 12:50 PM ET. Investors can register for the event in advance at Benzinga's website. The event's webcasts will be accessible on Lineage's Events and Presentations page.

Lineage Cell Therapeutics (LCTX) announced its fourth quarter and full year 2020 financial results, highlighting significant clinical and operational milestones. Total revenues decreased to $1.8 million for 2020, down from $3.5 million in 2019. Operating expenses were $27.9 million, a reduction of $14.1 million year-over-year. The net loss for 2020 was $20.6 million, or $0.14 per share. Importantly, Lineage secured $35.9 million in new capital, strengthening its financial position. The company aims to continue advancing its pipeline with key FDA meetings and clinical data presentations planned for 2021.

Lineage Cell Therapeutics, Inc. (LCTX) has raised $36 million through liquidating marketable securities and an at-the-market offering to fund operations through 2023. The company reported $57 million in cash and cash equivalents as of March 5, 2021. CEO Brian Culley emphasized value creation via these sales and advancing product candidates. Lineage's strong balance sheet provides flexibility for partnership discussions. Additionally, it has realized $32.5 million from OncoCyte share sales, holding shares currently valued at around $4.2 million.